HOME >> BIOLOGY >> NEWS
Vaccine hope for sufferers of potentially fatal stomach bug

Scientists at The University of Nottingham have been awarded over 366,000 to help unravel the mystery of a stomach bug which causes gastric ulcers and cancer. Their research could lead to the development of a vaccine for those most at risk.

The bacterium, Helicobacter pylori (Hp), lives in the stomachs of approximately half the worlds population. Dr Karen Robinson, a lecturer at the Centre of Biomolecular Sciences and co-researcher John Atherton, Professor of Gastroenterology and Head of the Wolfson Digestive Diseases Centre, lead a team of scientists that have spent the last three years trying to discover why most people are immune to the bug while it can cause potentially fatal disease in some people.

Dr Robinson says this new funding, from the Medical Research Council, will allow them to address one of the most important questions in Helicobacter research why some infected individuals develop ulcers or gastric cancer whilst others remain asymptomatic. My interest is in the immune response and how this dictates whether or not an infected person goes on to develop disease.

In recent studies the team has shown that the bacteria induce changes to the immune system which calm the inflammation down. However, sometimes this relationship goes wrong. Their experiments showed that people with ulcers often have a suppressed protective response, leading to the development of severe inflammation and ulceration of the stomach lining.

If we become infected with Hp it generally happens in childhood. The bacteria can remain undetected in the stomach for life. However, in some people it causes inflammation which leads to gastric ulcers or cancer in later years. Scientists at The University of Nottingham believe the Hp manipulates the immune system and patients arent aware of a problem until the disease has become so advanced they need surgery or chemotherapy.

The occurrence of the disease is currently thought to be due to
'"/>

Contact: Karen Robinson
44-011-582-31094
University of Nottingham
26-Apr-2007


Page: 1 2

Related biology news :

1. Vaccine trials inject hope into koalas future
2. Vaccine hope for malaria
3. Vaccine prevents prion disease in mice
4. Vaccine to cope with viral diversity in HIV
5. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
6. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
7. Vaccine-producing plant-factories
8. HPV Vaccine: Whats next
9. Vaccine shown effective against chancroid
10. Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax
11. Vaccine provides 100 percent protection against avian flu virus in animal study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vaccine hope for sufferers potentially fatal stomach bug

(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... which brings Q3 orders to $5.8 million and provides a good ... in North America and one in the ... bid new projects at record levels," said Peter Bruijns , ... at the end of Q3 than they have been for any ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
Cached News: